The effect and safety of small-molecule antiviral drugs on long prognosis of post-COVID-19 pulmonary fibrosis: a real-world study in China
Nearly half of PCPF patients experienced readmission within one-year following their initial hospitalization for acute COVID-19. Importantly, treatment with SMADs during the acute infection phase was significantly associated with a reduced readmission rate.
Authors
- Ying Xu (ORCID: https://orcid.org/0000-0001-6855-2934)
- Dan Peng (ORCID: https://orcid.org/0000-0001-7693-3788)
- Tieying Hou
- Fuqing Zhou
- Yawei Li
- Anqi Li
- Tianxin Xiang
- Ming Lu
- Xiaoling Den
Institutions
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Shenzhen Sixth People's Hospital (CN)
- ShenZhen People’s Hospital (CN)
- Nanchang Center for Disease Control and Prevention (CN)
- First Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Frontiers in Microbiology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fmicb.2025.1733465
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China